Roche presented results from the phase III SUNMO study, showing Lunsumio (mosunetuzumab) and Polivy (polatuzumab vedotin) combination therapy demonstrated a clinically meaningful and statistically significant improvement in progression-free survival and objective response rate compared to R-GemOx in people with relapsed or refractory large B-cell lymphoma. The combination therapy showed a 59% reduction in risk of disease progression or death and a median progression-free survival of 11.5 months, three times longer than R-GemOx. The safety profile of the combination therapy was consistent with the known profiles of the individual study medicines, potentially allowing use across outpatient and community settings. The incidence of cytokine release syndrome events was low, occurring in one in four patients. The combination therapy demonstrated a 12-month progression-free survival rate of 48.5%, more than doubled compared to R-GemOx. The overall survival data were not yet mature, but numerically favored the Lunsumio and Polivy combination therapy may provide a meaningful option for patients with relapsed or refractory large B-cell lymphoma. Roche's lymphoma portfolio is one of the broadest in the industry, providing a unique opportunity to combine regimens with different and complementary mechanisms of action. Lunsumio is already approved for people with relapsed or refractory follicular lymphoma in more than 60 countries worldwide. The SUNMO study results will be submitted to global health authorities, including the US Food and Drug Administration.